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This study focused at the potential of transforming growth factor b1 (TGF-b1) loaded gelatin microparticles to enhance the bone
response and mechanical strength of rabbit femoral defects ﬁlled with injectable calcium phosphate (CaP)/gelatin microparticle
composites. Therefore, TGF-b1 loaded composites and non-loaded controls were injected in circular defects as created in the femoral
condyles of rabbits and were left in place for 4, 8 and 12 weeks. The specimens were evaluated mechanically (push-out test), and
morphologically (scanning electron microscopy (SEM), histology, and histomorphometry). The results showed a gradual increase in
mechanical strength with increasing implantation periods. Histological and histomorphometrical evaluation showed similar results for
both composite formulations regarding histological aspect, new bone formation and bone/implant contact. However, TGF-b1 loading of
the composites demonstrated a signiﬁcant effect on composite degradation after twelve weeks of implantation. The results of this study
showed that CaP/gelatin composites show excellent osteogenic properties and a rapid increase in mechanical strength. The addition of
TGF-b1 signiﬁcantly enhances the bone remodeling process.
r 2007 Elsevier Ltd. All rights reserved.
Keywords: Injectable CaP cement; Gelatin microparticles; TGF-b1; Mechanical properties; Bone ingrowth1. Introduction
Calcium phosphate (CaP) ceramics are widely used as
bone substitutes in reconstructive orthopedic and oral
surgery because of their beneﬁcial effects on bone healing.
These ceramics can be applied as granules or prefabricated
porous blocks, but they can also be formulated as an
injectable CaP paste that can be shaped according to the
required dimensions [1–5]. These so-called CaP cements are
highly compatible with soft and hard tissues after setting in
situ [6]. In view of tissue reconstruction, CaP cements are
supposed to be subject of biological degradation and
concomitant replacement by bone tissue. However, thee front matter r 2007 Elsevier Ltd. All rights reserved.
omaterials.2007.10.029
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ess: J.Jansen@dent.umcn.nl (J.A. Jansen).degradation of CaP cements is known to be slow [7], which
is likely due to the limited extent of porosity. CaP cements
contain only an intrinsic nanoporosity that allows trans-
port of nutrients and waste through the material, but the
dimensions of this nanoporosity are insufﬁcient to obtain
tissue ingrowth [6]. As a consequence, attempts have been
made to increase the porosity of the material to allow tissue
ingrowth and to accelerate degradation [8,9]. For the
additional creation of microporosity, different methods
have already been applied; the most commonly used
method at our department is the incorporation of high
molecular weight poly(lactic-co-glycolic acid) (HMW-
PLGA) microparticles to generate CaP/PLGA composites
[9–12]. A limitation regarding the use of PLGA for
microparticle production is the relative slow degradation
of this polymer (6–12 weeks) [11]. This slow degradation
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in vivo application, which is the probable cause of delayed
bone formation in the composites [9,12–14].
Therefore, a method was developed to prepare compo-
sites in which microparticles of gelatin were incorporated
into CaP cement [15,16]. Gelatin microparticles are
biodegradable, biocompatible, and non-toxic and can be
crosslinked with glutaraldehyde in order to increase
thermal and mechanical stability of the microparticles
under physiological conditions [17]. Furthermore, the
crosslinking agent concentration and reaction period can
be varied, allowing the creation of microparticles with
different degradation properties [17–19].
Inherent to the creation of porosity is the loss of
mechanical strength of the CaP cement material. This
makes the composites less suitable for use under load-
bearing conditions. In an ideal situation, the cement would
retain its mechanical strength, while being resorbed and
replaced by newly formed bone. Previous research already
showed that the decreased mechanical properties are partly
compensated by the ingrowth of bone in the cement
porosity [12].
To further stimulate bone formation and cement
resorption, microparticles can be used for the delivery of
an appropriate growth factor. Among the candidate
growth factors for such an application is transforming
growth factor b1 (TGF-b1), which plays a signiﬁcant role
in wound healing [20–22] by enhancing the repair of injured
tissue like skin and bone [23]. TGF-b1 acts on osteoblasts,
chondrocytes, and cells of the osteoclastic lineage [24] and
has been reported to stimulate osteogenesis at orthotopic
sites [25–27].
In view of the above mentioned, this study investigated
the potential of TGF-b1 loaded gelatin microparticles to
enhance the bone response and mechanical strength of
rabbit femoral defects ﬁlled with injectable CaP/gelatin
microparticle composites.
2. Materials and methods
2.1. Calcium phosphate (CaP) cement
CaP cement (Calcibons; Merck Biomaterial GmbH, Darmstadt,
Germany) was used for the preparation of the implants. The chemical
composition of this cement is 61% a tri-calcium phosphate (a-TCP), 26%
CaHPO4, 10% CaCO3 and 3% precipitated hydroxyapatite (PHA).
Before usage, the cement powder was sterilized by gamma radiation with
25 kGy (Isotron B.V., Ede, The Netherlands).
2.2. Gelatin microparticles
Gelatin microparticles were prepared as described by Holland et al.
[28]. Brieﬂy, a gelatin solution was prepared by dissolving negatively
charged acidic gelatin (type B; pI ¼ 4.7–5.2; Sigma, St. Louis, MO, USA)
in deionized water at 37 1C for 1 h. Then, this solution was drop wise
added to 125ml chilled olive oil (Acros Organics, Geel, Belgium)
while stirring at 500 rpm. After 30min of stirring, 50ml chilled acetone
(4 1C; HPLC grade, Labscan Ltd., Dublin, Ireland) together with 500ml
25wt% glutaraldehyde (Merck, Darmstadt, Germany) was added to theemulsion. After an additional 30min of stirring, the microparticles were
collected by ﬁltration and washed with chilled acetone (4 1C). Finally, the
microparticles were frozen and lyophilized.
Microparticle size distribution was assessed by morphometrical
analysis using a light microscope (Leica Microsystems AG, Wetzlar,
Germany) and computer-based image analysis techniques (Leicas Qwin
Pro-image analysis system, Wetzlar, Germany).
2.3. TGF-b1 microparticle loading
For the TGF-b1-loaded composites, 600mg gelatin microparticles were
swollen in 3.6ml 4mM HCl/BSA [0.1%] solution containing 10mg TGF-b1
(R&D Systems Minneapolis, MI, USA), vortexed and lyophilized again.
This solution volume is below the microparticles’ theoretical swelling
volume in order to allow complete growth factor adsorption. In this way,
the positively charged TGF-b1 formed a polyionic complexation with the
negatively charged gelatin microparticles [29]. Eventually, 250 ng TGF-b1
was present within each implant.
2.4. Injectable CaP/gelatin composites
Composites containing 5% (w/w) gelatin microparticles were generated
as follows. Gelatin microparticles (30mg), either or not loaded with
TGF-b1, were pre-swollen in 180ml water and mixed for 15 s in a 2ml
syringe (Sherwood medical monoject) with closed tip using a mixing
apparatus (Silamat, Vivadent, Schaan, Liechtenstein) to obtain an even
distribution of the water content in the microparticles. CaP cement powder
(570mg) was added afterwards in the 2ml syringe. The ﬁnal composite was
created by mixing 210ml of Na2HPO4 (1wt%; ﬁlter sterilized) with 600mg
of this CaP/gelatin combination for 15 s using the mixing apparatus. After
mixing, the cement was immediately injected into the defect.
Final composite formulations in this study were:1. CaP/gelatin (5% w/w gelatin microparticles/CaP cement composite).2. CaP/gelatin+TGF-b1 (5% w/w TGF-b1-loaded gelatin micro-
particles/CaP cement composite; 250 ng TGF-b1 per composite).
Furthermore, additional samples were prepared with the goal to
determine the total porosity of the composites by correlating the weight
of CaP samples with the weight of the CaP/gelatin samples after placement
in a furnace at 650 1C for 2 h (to remove the gelatin microparticles) [11].
2.5. Surgery
Thirty-six female New Zealand White rabbits (4–5 months) with a
weight of approximately 3.5 kg were used as experimental animals. The
animal experiment was approved by the Animal Ethical Committee of the
Radboud University Nijmegen Medical Center and national guidelines for
the care and use of laboratory animals were observed. Each rabbit
received only one sample of both CaP/gelatin composite formulations.
The composites were inserted in trabecular bone defects as created in the
left medial and right medial distal femur [30]. In this way, 72 composites
were injected in 36 rabbits.
Surgery was performed under general inhalation anesthesia. Anesthesia
was induced by an intravenous injection of Hypnorm (0.315mg/ml
fentanyl citrate and 10mg/ml ﬂuanisone) and atropine, and maintained by
a mixture of nitrous oxide, isoﬂurane and oxygen through a constant
volume ventilator. To reduce the peri-operative infection risk, the rabbits
received antibiotic prophylaxis (Baytril 2.5% (enroﬂoxacin), 5–10mg/kg).
During anesthesia, the rabbits were immobilized on their back and
the surgical areas were shaved and disinfected with povidone–iodine.
A longitudinal incision was made down to the periosteum. Subsequently, a
midline incision was created in the periosteum. The periosteum was
undermined and lifted off the distal femora. The defects in the femora
were drilled from the medial direction with an increasing burr diameter
(from 2.0 to 4.0mm) to obtain cylindrical defects with a depth of 6mm
and a diameter of 4mm. Following injection of the composites, the
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periosteum and soft tissue were closed using resorbable vicryl 4–0 sutures.
The rabbits were sacriﬁced in groups of 12 at 4, 8 and 12 weeks (n ¼ 12
per formulation at each time period) post-surgery by an overdose of
Nembutals (pentobartital).
2.6. Mechanical testing (i.e. push-out test)
To determine the mechanical strength of the rabbit femoral defects
ﬁlled with CaP/gelatin composites, half of the retrieved specimens (n ¼ 6
for each composite formulation at each time point) were used. Evaluation
consisted of a push-out test [31,32], using a mechanical testing bench
(MTS 858 Mini Bionix II, Gouda, The Netherlands). The retrieved
specimens with their surrounding tissue were transported to the laboratory
on ice. After arrival, the distal femur was grinded at both sides to obtain
ﬂat surfaces, with the composite implant perpendicular to these ﬂat
surfaces to make the push-out test possible. Subsequently, each specimen
was ﬁxated on a support jig with a hole of 4.4mm (10% larger than the
implant diameter of 4.0mm) to minimize the effect of the test condition on
the push-out results [31,32]. This support jig enabled the application of a
vertical force using a 3.85mm diameter lever (at a constant displacement
speed of 0.5mm/min) on the CaP/gelatin specimens including the new
bone formation. When the peak force was reached, the test was
immediately stopped to ensure minimal displacement of the samples.
The mechanical strength of the defects ﬁlled with composites was
calculated by following formula:
shear strength ðMPaÞ
¼ Pushout forceðNÞ
p  implant diameter ðmmÞ  femoral thickness ðmmÞ .
2.7. Scanning electron microscopy (SEM)
After mechanical testing, the specimens were ﬁxated in 10% formalin
solution, dehydrated in a graded series of ethanol, and embedded in
methylmethacrylate. After polishing, the specimens were sputter-coated
with gold, and examined with SEM (Jeol 6310 SEM, Boston, MA, USA)
to determine the fracture plane as occurred during the push-out testing
(e.g. in the cement, at the interface bone–cement, in the surrounding
bone). SEM was performed at the Microscopic Imaging Center (MIC)
of the Nijmegen Center for Molecular Life Sciences (NCMLS), the
Netherlands.
2.8. Histological and histomorphometrical evaluation
The other half of the retrieved implants with their surrounding tissue
(six specimens of each experimental group at each time point) were
prepared for histological evaluation. The samples were ﬁxated in 4%
formalin solution (pH=7.4), dehydrated in a graded series of ethanol, and
embedded in methylmethacrylate. Following polymerization, three 10 mm
thick, longitudinal sections were prepared per specimen through the
center of the composites, using a sawing microtome technique [33]. The
sections were stained with methylene blue and basic fuchsin and
investigated using a light microscope. For histomorphometrical analysis,
all sections per specimen were evaluated using computer based image
analysis software (Leicas Qwin Pro-image analysis system, Wetzlar,Table 1
Implant porosity, gelatin microparticle sizes and TGF-b1 loading
CaP/gel
Macroporosity 45.071
Microparticles size (before swelling) 8.477.6
Microparticles size (after swelling) 20.771
TGF-b1 loading –Germany). The quantitative evaluation of newly formed bone was done by
determining a region of interest (ROI), which was set using a circle of
4.0mm in diameter with the composite positioned in the center. Within
this ROI, new bone formation was distinguished from composite through
structure and color differences. New bone formation was expressed in
mm2, using standardization of the two-dimensional area of analysis.
Bone/implant contact evaluation was deﬁned by the percentage of
composite perimeter at which direct bone to composite contact, without
an intervening soft tissue layer, was present. Degradation of the CaP/
gelatin composites was determined by calculating the remaining surface
area of the composites through structure and color differences. The
remaining composite was expressed in mm2, using standardization of the
two-dimensional area of analysis.
2.9. Statistical analysis
Statistical analysis was performed with GraphPads Instat 3.05
software (GraphPad Software Inc., San Diego, CA, USA) using one-
way analysis of variance (ANOVA) with a Tukey multiple comparison
post-test. Signiﬁcance was set at po0.05.
3. Results
3.1. Composite characterization
The distribution of the unswollen gelatin microparticles
varied between 1 and 49 mm with an average size of
8.477.6 mm, while the water-swollen microparticles varied
between 1 and 66 mm with an average size of 20.7714.6 mm.
The porosity of the composite formulations after setting
was 45.071.3% (Table 1).
3.2. General observations of animals
All 36 rabbits in this experiment remained in good health
and did not show any wound complications after surgery.
The original defects were completely ﬁlled with the
injectable composites without the presence of entrapped
air bubbles. At retrieval, no visual signs of inﬂammatory or
adverse tissue reactions were observed.
3.3. Mechanical testing
The results of the push-out test (Fig. 1) showed a gradual
increase in mechanical strength with increasing implantation
periods. After 4 weeks of implantation, the push-out value
of the CaP/gelatin composites including new bone formation
was 3.771.7MPa, which increased to 6.671.6MPa at
8 weeks, and ﬁnally measured 10.072.9MPa after 12 weeks
of implantation. The CaP/gelatin+TGF-b1 compositesatin CaP/gelatin+TGF-b1
.3%
mm (1–49mm)
4.6mm (1–66mm)
250ng
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Fig. 1. Push-out test results (in MPa) of CaP/gelatin composites with or
without TGF-b1 after 4, 8 and 12 weeks of implantation. Bars represent
means7SD (n ¼ 6).
Fig. 2. Scanning electron microscopy (SEM) of CaP/gelatin composites
with or without TGF-b1 after 4 (A), 8 (B) and 12 (C) weeks of
implantation. CaP/Gel ¼ calcium phosphate cement with incorporated
gelatin microparticles; B ¼ trabecular bone; F ¼ fracture (plane);
N ¼ newly formed bone.
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strength value of 2.970.7MPa after 4 weeks of implanta-
tion, which increased to 4.973.0MPa at 8 weeks, and ﬁnally
measured 9.173.6MPa after 12 weeks of implantation. At
individual implantation periods, no signiﬁcant differences of
mechanical strength values were present between CaP/
gelatin and CaP/gelatin+TGF-b1 composite formulations.
3.4. Scanning electron microscopy (SEM)
SEM examination (Fig. 2) of the fracture plane of the
specimens subjected to the mechanical test showed similar
results for CaP/gelatin and CaP/gelatin+TGF-b1 compo-
sites. After 4 weeks of implantation, samples showed a
fracture plane at the bone–cement interface (Fig. 2A),
while the 8-week samples showed a fracture, which was
found in the CaP/gelatin composites, as well as in the newly
formed bone (Fig. 2B). Finally, the 12 week samples
demonstrated fractures only in the newly formed bone
(Fig. 2C).
3.5. Histological and histomorphometrical evaluation
Histological evaluation showed similar results for CaP/
gelatin and CaP/gelatin+TGF-b1 composites (Fig. 3).
Within ﬁrst 4 weeks after implantation, limited bone
formation occurred at the implant periphery, whereas after
8 weeks of implantation peripheral microparticles were
degraded and replaced by newly formed bone. Finally,
after 12 weeks of implantation more bone ingrowth was
observed deeper into the composites, but no tissue
formation was present in the central part of the composites.
Furthermore, degradation of the composites was observed,
indicated by the loss of integrity of the implant and by the
decline in composite diameter and concomitant replace-
ment by newly formed bone with increasing implantation
time. Also, this newly formed bone around the composites
appeared to be denser than the surrounding trabecularbone. In three samples (out of 36), an intervening ﬁbrous
tissue layer was observed between composite and sur-
rounding bone. One was found after 8 weeks of implanta-
tion in the CaP/gelatin group, while the other two were
found in the CaP/gelatin+TGF-b1 at 4 and 8 weeks of
implantation. None of the composites were associated with
the presence of multi-nucleated giant cells.
Histomorphometrical evaluation showed no signiﬁcant
differences between formulations containing CaP/gelatin or
CaP/gelatin+TGF-b1 (Fig. 4). Bone ingrowth into the CaP/
gelatin composites after 4 weeks of implantation was
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Fig. 3. Histological sections of CaP/gelatin+TGF-b1 composites after 4
(A), 8 (B), and 12 (C) weeks of implantation (dashed circle marks the
original defect).
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Fig. 4. Bone ingrowth (in mm2) into the CaP/gelatin composites with or
without TGF-b1 after 4, 8 and 12 weeks of implantation. Bars represent
means7SD (n ¼ 6).
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Fig. 5. Bone/implant contact (in %) of the CaP/gelatin composites with or
without TGF-b1 after 4, 8 and 12 weeks of implantation. Bars represent
means7SD (n ¼ 6).
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and ﬁnally measured 2.271.0mm2 after 12 weeks of
implantation. CaP/gelatin+TGF-b1 composites showed
bone ingrowth of 1.070.7mm2 after 4 weeks of implanta-
tion, which increased to 1.770.9mm2 at 8 weeks, and ﬁnally
measured 3.872.0mm2 after 12 weeks of implantation.
Bone/implant contact of the CaP/gelatin composites
(Fig. 5) after 4 weeks of implantation was 61.0711.4%,
which after 8 weeks measured 64.8715.1%, and ﬁnally was
64.2715.8% after 12 weeks of implantation. CaP/gelatin+TGF-b1 composites showed a bone/implant con-
tact of 54.6710.2% after 4 weeks of implantation, which
after 8 weeks measured 62.974.8%, and ﬁnally was
53.778.0% after 12 weeks of implantation.
The remaining surface area of the CaP/gelatin composites
(Fig. 6) after 4 weeks of implantation was 11.271.0mm2,
which decreased to 9.271.0mm2, and ﬁnally measured
7.771.7mm2 after 12 weeks of implantation. CaP/
gelatin+TGF-b1 composites showed a remaining surface
area of 10.471.0mm2 after 4 weeks of implantation, which
decreased to 8.472.0mm2 at 8 weeks, and ﬁnally measured
3.872.3mm2 after 12 weeks of implantation. The difference
between CaP/gelatin composites and CaP/gelatin+TGF-b1
was signiﬁcant after 12 weeks of implantation.
4. Discussion
In this study, the bone response and mechanical strength
of a rabbit femoral defect ﬁlled with an injectable CaP
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Fig. 6. Remaining surface area (mm2) of the CaP/gelatin composites with
or without TGF-b1 after 4, 8 and 12 weeks of implantation. Bars represent
means7SD (n ¼ 6). (*po0.05.)
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loaded with TGF-b1, was examined. The loading of gelatin
microparticles with TGF-b1 was enrolled as a parameter to
evaluate potential effects of this growth factor on bone
formation and cement resorption.
The porosity of both composite formulations (CaP/
gelatin with or without TGF-b1) was 45.071.3%, which
should be high enough to obtain an interconnective
network after microparticle degradation [33]. Nonetheless,
no ﬁbrous tissue or bone formation was observed in the
central part of the implants. This might be due to the
delayed degradation of gelatin microparticles in the central
part of the composites, or the relatively low mass ratio of
microparticles (5wt%) in the composite formulations. The
lack of interconnectivity might further be explained by the
formation of apatite crystals on gelatin, which has been
reported previously [15,34]. This phenomenon might cause
ﬁlling of the created pores with precipitate, and hence
hamper the formation of an interconnective network. This
problem can be solved partly by increasing the mass ratio,
but we know also that setting problems occur if the mass
ratio is above a certain threshold [15], which makes such
composite formulations unfavorable for clinical usage.
In this study, implants were grinded to obtain a ﬂat
surface for the push-out test. Still, parameters like
composite thickness, composite diameter, angularity of
the bone defect and positioning of the lever can inﬂuence
the results of the push-out test [31]. Nevertheless, the push-
out results represent an approximation of the actual
mechanical strength. Remarkably, the results of the push-
out test showed similar or even higher values compared to
the compression strength of 4–10MPa of trabecular bone
[35–37]. This observation is in accordance with Ikenaga
et al. [37], who also found massive new bone formation
around degraded CaP cement, which was mainly composed
of b-TCP. This new bone formation resulted in an
increased bone density directly around the degradedimplant, and hence higher push-out values of the compo-
sites compared to trabecular bone. Furthermore, the
applied push-out test utilizes a similar lever for all samples.
In view of composite degradation and replacement by
newly formed bone at later implantation periods, the used
method is not testing the actual interface of the composite
with the bone tissue of these samples, but rather the denser
bone structure directly around the degraded composite.
The increase in mechanical strength with implantation time
was further conﬁrmed by SEM examination, which
evidently supports the suggestion that the composite
appears to be suitable for load-bearing purposes.
Histological evaluation showed that bone ingrowth
started at the defect edges and proceeded into the
micropores, which were created after degradation of the
gelatin microparticles. This was also observed in other
in vivo experiments with CaP cement based composites
[12,13,38]. This might be due to the already excellent
osteogenic properties of the CaP cement. Kroese-Deutman
et al. [39] reported that porous CaP cement itself was
sufﬁcient to bridge a critical-sized cranial defect in rabbits,
without the presence of any growth factors. On the other
hand, the cement material in their study did not show a
clear sign of degradation despite the complete ﬁlling of the
implant porosity with bone tissue. This is in contrast to the
current study where the TGF-b1 loaded specimens were
signiﬁcantly more degraded than the non-loaded speci-
mens, which suggests that the released TGF-b1 evoked an
enhanced bone remodeling resulting in increased cement
degradation.
Further, it has to be noticed that we decided to employ a
dose of 250 ng TGF-b1 (3.3 ng per mm3 implant) per
injectable composite. Since the optimal TGF-b1 concen-
tration is unknown, the amount of included TGF-b1
was based on previous research [40]. Amounts of 0.5 ng
TGF-b1 per mm3 implant have been reported to have an
effect on bone formation in a rat cranial defect [41]. Also,
Vehof et al. [42] and Beck et al. [43] both described the
incorporation of up to 25 ng TGF-b1 per mm3 implant to
have an effect on bone formation in a rabbit cranial defect.
Considering the release kinetics of TGF-b1 from the
gelatin/CaP composite, previous research by Habraken
et al. [44] showed that the release of TGF-b1 from gelatin
microparticles incorporated in CaP cement was limited to
14%, and that the release of adsorbed TGF-b1 on CaP
cement alone was limited to 33% after 6 weeks of
incubation. From literature, it is further known that CaP
cements have a strong binding afﬁnity for proteins [45,46].
Most likely, after degradation of the gelatin microparticles,
the released TGF-b1 was bound to the CaP cement, which
after cement degradation was released again. Therefore,
the released TGF-b1 is still able to stimulate the bone
response after longer implantation periods. Besides, it is
proposed that even in a biomaterial-bound state, a growth
factor can retain its biological activity [47,48].
Although almost all implants showed good bone
ingrowth, three samples showed an intervening ﬁbrous
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could be explained by an initially suboptimal bone/implant
contact, which can result in ﬁbrous tissue formation [12].
The added water inside the gelatin microparticles and the
presence of body ﬂuids can contribute to a delayed setting
time [15,49]. This hampers setting of the composite on the
defects periphery, and can lead to composite material being
ﬂushed away at the bone defect wall. Although bleeding of
the bone defects was tried to be minimized by packing the
defects with gauzes before injecting the composites, the
presence of limited amounts of blood at the defect site
could not be completely prevented.
The bone/implant contact measurements showed a
contact of approximately 60% during all implantation
periods. Ooms et al. [7] reported that a CaP cement without
microparticles resulted in a bone/implant contact of
80–90%. By adding microparticles in the CaP cement the
surface area of the CaP cement is increased after
degradation of the microparticles. Therefore, new bone
formation has to ﬁll up the created pores, which might
explain the differences in bone/implant contact with dense
CaP cement.5. Conclusions
In conclusion, this study demonstrated that after
injection and setting of a CaP/gelatin composite, the
mechanical strength of the composite including the new
bone formation, is sufﬁcient after 12 weeks of implantation
for load-bearing purposes. Further, degradation of the
composites was observed, indicated by the loss of integrity
of the composites, and by the decline in composite diameter
and concomitant replacement by newly formed bone with
increasing implantation time. The addition of TGF-b1 to
the gelatin microparticles in the composite formulation did
not result in higher mechanical strength values or
improvement of the bone response, but signiﬁcantly
increased composite degradation after 12 weeks of
implantation.Acknowledgments
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